Skip to main content
AMRX
NASDAQ Life Sciences

Amneal Finalizes Nationwide Opioid Settlement, Resolving Major Legal Overhang

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$13.97
Mkt Cap
$4.385B
52W Low
$6.685
52W High
$14.66
52W Position info
109% above low
Off High info
4.7% below high
Rel. Volume info
4.9× avg
Market data snapshot near publication time

AMRX has more than doubled off its 52-week low of $6.685 on elevated volume (4.9× avg).

Summary

Amneal Pharmaceuticals has finalized its nationwide agreement to settle a substantial majority of opioids-related claims, involving up to $132.9 million in cash and significant naloxone product contributions.


Key Events · Legal and Risk Events · AMRX

  • Opioid Settlement Finalized

    Amneal Pharmaceuticals has made effective its nationwide agreement to settle a substantial majority of opioids-related claims, becoming effective January 29, 2026.

  • Financial Terms

    The settlement includes an $88.5 million cash payment and up to $177.4 million in naloxone nasal spray, with an option for settling parties to receive up to an additional $44.4 million in cash.

  • Resolution of Legal Overhang

    This agreement resolves a significant legal liability, removing uncertainty and potential future litigation costs related to opioid claims, which is a positive development for the company.


Analysis · AMRX · Life Sciences

This 8-K filing announces the finalization of Amneal Pharmaceuticals' nationwide opioid settlement, a critical development that resolves a significant legal and financial overhang for the company. The agreement, which becomes effective on January 29, 2026, involves a cash payment of $88.5 million and up to $177.4 million in naloxone nasal spray, with an option for settling parties to receive up to an additional $44.4 million in cash in lieu of product. The total potential cash outlay of up to $132.9 million represents a material financial commitment, but the resolution of these widespread claims removes substantial uncertainty and potential future litigation costs. This positive news comes as the stock trades near its 52-week high, potentially reinforcing investor confidence in the company's future.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMRX was trading at $13.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $6.69 to $14.66. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMRX - Latest Insights

AMRX
Nov 17, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.12
Real-time Price: $21.67 info
Change: +$0.550 (+3%) info
Market Cap: $7.453B info
AMRX
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.28
Real-time Price: $21.67 info
Change: +$0.390 (+2%) info
Market Cap: $7.453B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.23
Real-time Price: $21.67 info
Change: +$1.44 (+7%) info
Market Cap: $7.453B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.20
Real-time Price: $21.67 info
Change: +$1.47 (+7%) info
Market Cap: $7.453B info
AMRX
Oct 23, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $20.38
Real-time Price: $21.67 info
Change: +$1.29 (+6%) info
Market Cap: $7.453B info